Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

ctDNA Monitoring of Patients With ER-Positive, HER2-Negative High Risk Breast Cancer During Adjuvant Endocrine Therapy

Featuring Lajos Pusztai, MD, DPhil 

 

Lajos Pusztai, MD, DPhil, Yale Cancer Center, New Haven, Connecticut,discussed results from the DARE study which analyzed the clinical utility of ctDNA monitoring during adjuvant endocrine therapy to detect molecular relapse before apparent recurrence. 

These results were first reported at the 2023 San Antonio Breast Cancer Symposium. 


Source: 

Pusztai L, Kalashnikova E, Hobbs E, et al. Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract PS06-02

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

Advertisement